Skin Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Skin
| Protocol | ECOG EA6141 |
|---|---|
| Cancer Type: | Melanoma-unresectable |
| Fast Facts |
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
| Protocol | EA6192 |
|---|---|
| Cancer Type: | Advanced Melanoma |
| Fast Facts |
A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
| Protocol | SWOG S2000 |
|---|---|
| Cancer Type: | Melanoma with Brain Metastases |
| Fast Facts |
A Randomized Phase 2 Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Brafv600-Mutant Melanoma with Brain Metastases
| Protocol | EA6194 |
|---|---|
| Cancer Type: | Operable Melanoma |
| Fast Facts |
Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study
| Protocol | SWOG S2015 |
|---|---|
| Cancer Type: | primary cutaneous melanoma |
| Fast Facts |
Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
| Protocol | Alliance A091903 |
|---|---|
| Cancer Type: | RESECTED MUCOSAL MELANOMA |
| Fast Facts |
A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA
| Protocol | SWOG S2101 |
|---|---|
| Cancer Type: | melanoma |
| Fast Facts |
S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study.
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EA6174 |
|---|---|
| Cancer Type: | Merkel Cell Carcinoma |
| Fast Facts |
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A091802 |
|---|---|
| Cancer Type: | Carcinoma of the Skin |
| Fast Facts |
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
